AVAX ANNOUNCES LAUNCH OF M-VAX FOR THE TREATMENT OF PATIENTS WITH STAGE III & IV MELANOMA IN SWITZERLAND

AVAX Technologies, Inc. (OTCMarket:AVXT.OB) announces the commencement of the commercial launch of M-Vax, its AC Vaccine product candidate for the treatment of melanoma, in Switzerland through its Swiss distribution partner Pro Vaccine AG based in Baar, Switzerland. Marketing of M-Vax has started after receiving authorization from the Swiss Federal Office of Public Health (FOPH) for the import and export of the product in accordance with the law for Control of Transplantation (SR 818.111) passed in March 1996. The vaccine will be produced by AVAX's wholly owned subsidiary, Genopoietic SAS, based in Lyon, France.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1075059XSL_NEWSML_TO_NEWSML_WEB.xml)